Interleukin-18 as a drug repositioning opportunity for inflammatory bowel disease: A Mendelian randomization study. (2019)
Attributed to:
Mendelian randomization to hypothesis-free causal inference
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1038/s41598-019-45747-2
PubMed Identifier: 31253830
Publication URI: http://europepmc.org/abstract/MED/31253830
Type: Journal Article/Review
Volume: 9
Parent Publication: Scientific reports
Issue: 1
ISSN: 2045-2322